Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant PK Study in Healthy Females
NCT03324061Phase 1Completed
- Sponsor
- Eagle Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fulvestrant in breast cancer (2 arms), sponsored by Eagle Pharmaceuticals. Primary endpoint: Pharmacokinetic parameters. Started Nov 2017; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03324061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03324061.